Cerulean Scientific

Cerulean Scientific is a private medical device company on a mission to reengineer the standard of care by solving the pervasive problem of medical device failure due to clogging, obstruction, and biofouling. The company leverages a proprietary, physics-based surface technology platform to create devices that dramatically resist failure, with initial applications in neurosurgery (hydrocephalus shunts) and vascular access (hemodialysis catheters). Cerulean partners with leading academic clinicians and researchers, and its technology has shown compelling preclinical results, including a 0% clogging rate for its hemodialysis catheter versus 100% for a leading competitor in a 90-day sheep study.

A proprietary, physics-based surface technology designed to prevent clogging, obstruction, and biofouling in medical devices by resisting cellular and protein adhesion without pharmacological agents.

Cerulean faces competition from large medical device companies like Medtronic, Integra, and BD in its target markets. Its differentiation is a physics-based surface technology focused directly on preventing mechanical clogging and biofouling, rather than adjunctive features like programmable valves or antimicrobial coatings offered by incumbents.